Clinical Trial

Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 26, 2022 (before its estimated March 1, 2023 completion). Its status may not reflect the trial's current state.
Summary
Locoregional (LRT) of the primary tumor in de-novo metastatic breast cancer (dnMBC) is no longer only a surgical challenge, but more the final decision of a multidisciplinary tumor board including medical oncologists, radiation oncologists and surgical oncologists. It is no longer only a question of locoregional control but rather a wider issue of improving overall survival (OS), due to the possible biological link between primary tumor and metastases. A multimodal approach, including LRT with curative intent should be considered for selected dnMBC patients, especially for the subset of bone-only metastatic ones.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-04-12.
Trial Details
NCT Number NCT05334459
Lead Sponsor Ankara Oncology Research and Training Hospital
Conditions Metastatic Breast Cancer
Enrollment 40 participants
Start Date 2022-03-01
Primary Completion 2023-03-01 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2022-04-26